Mechelen Belgium; 10 March 2017 Galapagos NV Euronext & NASDAQ GLPG announces two new Phase 2 studies investigating Âfilgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by filgotini...
↧